Loading…
Psychedelics as Medicines: An Emerging New Paradigm
Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depressio...
Saved in:
| Published in: | Clinical pharmacology and therapeutics 2017-02, Vol.101 (2), p.209-219 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83 |
| container_end_page | 219 |
| container_issue | 2 |
| container_start_page | 209 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 101 |
| creator | Nichols, DE Johnson, MW Nichols, CD |
| description | Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation‐related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched. |
| doi_str_mv | 10.1002/cpt.557 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1853350962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1853350962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83</originalsourceid><addsrcrecordid>eNp1kEtLAzEURoMotlbxH8jsLMjUPCYzibtS6gOqdlHXIU1uamRmWpOW0n9vSqs7V5cLh8PHQeia4AHBmN6b1XrAeXWCuoQzmpec8VPUxRjLXFJWdtBFjF_pLaQQ56hDBSYS07KL2DTuzCdYqL2JmY7ZK1hvfAvxIRu22biBsPDtInuDbTbVQVu_aC7RmdN1hKvj7aGPx_Fs9JxP3p9eRsNJbhipqrwgRjhrtWSOUMGIcQ4KLeeV5EAcJSXWrqyMrIgBqallBStEWk60qcBawXqof_CuwvJ7A3GtGh8N1LVuYbmJigjOGMeypAm9PaAmLGMM4NQq-EaHnSJY7QupVEilQom8OUo38wbsH_ebJAF3B2Dra9j951Gj6Wyv-wHiPG0p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1853350962</pqid></control><display><type>article</type><title>Psychedelics as Medicines: An Emerging New Paradigm</title><source>Wiley</source><creator>Nichols, DE ; Johnson, MW ; Nichols, CD</creator><creatorcontrib>Nichols, DE ; Johnson, MW ; Nichols, CD</creatorcontrib><description>Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation‐related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.557</identifier><identifier>PMID: 28019026</identifier><language>eng</language><publisher>United States</publisher><subject>Anxiety - drug therapy ; Brain - drug effects ; Brain - metabolism ; Clinical Trials as Topic ; Depression - drug therapy ; Dose-Response Relationship, Drug ; Hallucinogens - administration & dosage ; Hallucinogens - adverse effects ; Hallucinogens - pharmacology ; Hallucinogens - therapeutic use ; Humans ; Inflammation - drug therapy ; Inflammation - physiopathology ; Inflammation Mediators - metabolism ; Lysergic Acid Diethylamide - therapeutic use ; Mental Disorders - drug therapy ; Mind-Body Therapies - methods ; Obsessive-Compulsive Disorder - drug therapy ; Psilocybin - therapeutic use ; Psychotherapy - methods ; Receptor, Serotonin, 5-HT2A - biosynthesis ; Serotonin 5-HT2 Receptor Agonists - pharmacology ; Severity of Illness Index ; Substance-Related Disorders - drug therapy</subject><ispartof>Clinical pharmacology and therapeutics, 2017-02, Vol.101 (2), p.209-219</ispartof><rights>2016 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2016 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83</citedby><cites>FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.557$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.557$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28019026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nichols, DE</creatorcontrib><creatorcontrib>Johnson, MW</creatorcontrib><creatorcontrib>Nichols, CD</creatorcontrib><title>Psychedelics as Medicines: An Emerging New Paradigm</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation‐related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.</description><subject>Anxiety - drug therapy</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Clinical Trials as Topic</subject><subject>Depression - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Hallucinogens - administration & dosage</subject><subject>Hallucinogens - adverse effects</subject><subject>Hallucinogens - pharmacology</subject><subject>Hallucinogens - therapeutic use</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - physiopathology</subject><subject>Inflammation Mediators - metabolism</subject><subject>Lysergic Acid Diethylamide - therapeutic use</subject><subject>Mental Disorders - drug therapy</subject><subject>Mind-Body Therapies - methods</subject><subject>Obsessive-Compulsive Disorder - drug therapy</subject><subject>Psilocybin - therapeutic use</subject><subject>Psychotherapy - methods</subject><subject>Receptor, Serotonin, 5-HT2A - biosynthesis</subject><subject>Serotonin 5-HT2 Receptor Agonists - pharmacology</subject><subject>Severity of Illness Index</subject><subject>Substance-Related Disorders - drug therapy</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLAzEURoMotlbxH8jsLMjUPCYzibtS6gOqdlHXIU1uamRmWpOW0n9vSqs7V5cLh8PHQeia4AHBmN6b1XrAeXWCuoQzmpec8VPUxRjLXFJWdtBFjF_pLaQQ56hDBSYS07KL2DTuzCdYqL2JmY7ZK1hvfAvxIRu22biBsPDtInuDbTbVQVu_aC7RmdN1hKvj7aGPx_Fs9JxP3p9eRsNJbhipqrwgRjhrtWSOUMGIcQ4KLeeV5EAcJSXWrqyMrIgBqallBStEWk60qcBawXqof_CuwvJ7A3GtGh8N1LVuYbmJigjOGMeypAm9PaAmLGMM4NQq-EaHnSJY7QupVEilQom8OUo38wbsH_ebJAF3B2Dra9j951Gj6Wyv-wHiPG0p</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Nichols, DE</creator><creator>Johnson, MW</creator><creator>Nichols, CD</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201702</creationdate><title>Psychedelics as Medicines: An Emerging New Paradigm</title><author>Nichols, DE ; Johnson, MW ; Nichols, CD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anxiety - drug therapy</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Clinical Trials as Topic</topic><topic>Depression - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Hallucinogens - administration & dosage</topic><topic>Hallucinogens - adverse effects</topic><topic>Hallucinogens - pharmacology</topic><topic>Hallucinogens - therapeutic use</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - physiopathology</topic><topic>Inflammation Mediators - metabolism</topic><topic>Lysergic Acid Diethylamide - therapeutic use</topic><topic>Mental Disorders - drug therapy</topic><topic>Mind-Body Therapies - methods</topic><topic>Obsessive-Compulsive Disorder - drug therapy</topic><topic>Psilocybin - therapeutic use</topic><topic>Psychotherapy - methods</topic><topic>Receptor, Serotonin, 5-HT2A - biosynthesis</topic><topic>Serotonin 5-HT2 Receptor Agonists - pharmacology</topic><topic>Severity of Illness Index</topic><topic>Substance-Related Disorders - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nichols, DE</creatorcontrib><creatorcontrib>Johnson, MW</creatorcontrib><creatorcontrib>Nichols, CD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nichols, DE</au><au>Johnson, MW</au><au>Nichols, CD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychedelics as Medicines: An Emerging New Paradigm</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2017-02</date><risdate>2017</risdate><volume>101</volume><issue>2</issue><spage>209</spage><epage>219</epage><pages>209-219</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><notes>This article was published online on 4 November 2016. After online publication, revisions were made to the text. This notice is included in the online and print versions to indicate that both have been corrected on 13 January 2016.</notes><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation‐related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.</abstract><cop>United States</cop><pmid>28019026</pmid><doi>10.1002/cpt.557</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2017-02, Vol.101 (2), p.209-219 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1853350962 |
| source | Wiley |
| subjects | Anxiety - drug therapy Brain - drug effects Brain - metabolism Clinical Trials as Topic Depression - drug therapy Dose-Response Relationship, Drug Hallucinogens - administration & dosage Hallucinogens - adverse effects Hallucinogens - pharmacology Hallucinogens - therapeutic use Humans Inflammation - drug therapy Inflammation - physiopathology Inflammation Mediators - metabolism Lysergic Acid Diethylamide - therapeutic use Mental Disorders - drug therapy Mind-Body Therapies - methods Obsessive-Compulsive Disorder - drug therapy Psilocybin - therapeutic use Psychotherapy - methods Receptor, Serotonin, 5-HT2A - biosynthesis Serotonin 5-HT2 Receptor Agonists - pharmacology Severity of Illness Index Substance-Related Disorders - drug therapy |
| title | Psychedelics as Medicines: An Emerging New Paradigm |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A55%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychedelics%20as%20Medicines:%20An%20Emerging%20New%20Paradigm&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Nichols,%20DE&rft.date=2017-02&rft.volume=101&rft.issue=2&rft.spage=209&rft.epage=219&rft.pages=209-219&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.557&rft_dat=%3Cproquest_cross%3E1853350962%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3177-41c8fdda93f12831cffe4a9b795e1f2160af67c971ce9a2d343486531ac7edd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1853350962&rft_id=info:pmid/28019026&rfr_iscdi=true |